• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Hypolipidemic Agents
    26 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    not in the basket chart

    Omega-3 300 mg (DHA 120 mg, EPA 180 mg).
    CAPS: 210. 1 cap dly, dur.
    Nutritional supplement.
    C/I: Hypersens.

    Alsepa Super
    not in the basket chart
    Alsepa Super

    Omega-3 600 mg.
    CAPS: 120. 1-3 caps dly, dur. meal.
    Nutritional supplement.
    C/I: Hypersens.

    Atorvastatin Teva
    partial basket chart
    Atorvastatin Teva

    Statin. Atorvastatin 10, 20, 40, 80 mg.
    F.C. TABS: 30 x 10 mg, 20 mg, 40 mg, 80
    mg. Prim. hypercholesterolem. incl.
    famil. hypercholesterolem.
    (heterozygous variant)/comb. (mixed)
    hyperlipidemia (Fredrickson types IIa,
    IIb): Initial: 10-20 mg 1 x dly. Pts. requir.
    large reduct. in LDL (>45%): 40 mg 1 x
    dly. Dos. range: 10-80 mg 1 x dly. To be
    individualiz. Homozygous famil.
    hypercholesterolem: 10-80 mg 1 x dly
    as adjuv. to other lipid-lower. tmt or if
    such tmts unavail. Heterozygous famil.
    hypercholesterolem in ped. pts (10-17
    yrs): Initial: 10 mg dly; max: 20 mg dly.
    To be individualiz. Prevent. CV/
    cerebrovasc. events: 10 mg dly. Higher
    dos. may be necessary. Hepat. insuffic:
    Perform liver tests bef. initiat. tmt, at 6
    and 12 wks aft. initiat./elevat. dose and
    periodic. (e.g. semi-annually). Ren.
    insuffic: No dose adjust. req. Elderly: As
    gen. populat.
    Hypercholesterolem: Adjuv. to diet for
    reduct. elevat. total cholesterol LDLcholesterol
    apolipoprotein B and
    triglycerides and to increase HDL
    cholesterol in pts with prim.
    hypercholesterolem. when response to
    diet and other nonpharmacolog.
    measures is inadeq; to reduce total-C and
    LDL-C in pts. with homozygous familial
    hypercholesterolem. as an adjunct to
    other lipid-lower. tmt. (e.g. LDL apheres.)
    or if such tmts are unavail. Ped. pts (10-17
    yrs): Adjuv. to diet to reduce total -C, LDL-C
    and apo B levels in boys and
    postmenarchal girls with heterozygous
    famil. hypercholesterolem. Prevent. CV
    dis./cerebrovasc. event: Adjuv. to correct.
    other risk factors such as hypertens. Pts.
    with clinic. evident coronary heart dis:
    Reduce risk of non-fatal MI; reduce risk of
    fatal and non fatal stroke; reduce risk of
    hospitalizat. for CHF; reduce risk of
    angina. Reduce risk revascular. proced.
    C/I: Hypersens., active liver dis./
    unexplained persist. elevats. serum
    transaminases exceeding 3 x upper limit
    of normal; myopath., pregn./lact.;
    women of childbear. potent. not using
    approp. contracept. measures.

    partial basket chart
    Multiple ingredients

    HMG-CoA Reductase Inhibitor, Lipid Modifying Agent. Ezetimibe 10 mg, Atorvastatin 10, 20, 40, 80 mg.
    F.C. TABS.: 30. Hypercholesterolaemia and/or CHD with ACS History). The pt. should be on an appropriate lipid-lower. diet and should cont. on this diet during tmt. with this drug.
    The dose range is 10/10 mg/d. through 10/80 mg/d. The typical dose is 10/10 mg ×1/d. The pt’s. low-density lipoprotein cholesterol (LDL-C) level, CHD status, and response to current cholesterol-lower. ther. should be consid. when starting ther. or adjust. the dose.
    The dose should be individual. based on the known efficacy of the various dose strengths of and the response to the current cholesterol-lower. ther. Adjust. of dose should be made at intervals of 4 wks. or more.
    HoFH: 10/10-10/80 mg dly. The drug  may be used as an adjunct to other lipid-lower. tmts. (e.g., LDL apheresis) in these pts. or if such tms. are unavailab.
    May be taken with/without food.
    Prevent. of Cardiovasc. Event: Indicat. to reduce the risk of cardiovasc. events in pts. with coron. heart dis.(CHD) and a hist. of acute coron. syndr. (ACS), either previous. treated with a statin or not.
    Hypercholesterolaemia: The drug  indicat. as adjunct. ther. to diet for use in adult. with prim. (heterozygous famil. and non-famil.) hypercholesterolaemia or mixed hyperlipidaemia where use of a comb. product is appropriate, pts. not appropriat. control. with a statin alone, pts. already treated with a statin and ezetimibe.
    Homozyg. Familial Hypercholesterolaemia (HoFH): Indicat. as adjunct. ther. to diet for use in adults with HoFH. Pts. may also receive adjunct. tmts. (e.g., low-density lipoprotein [LDL] apheresis).
    C/I: Hypersens. Preg., lact. , and in women of child-bear. potent.

    Bezafibrate 400 SR
    full basket chart
    Bezafibrate 400 SR

    Fibrate. Bezafibrate 400 mg.
    S.R. TABS: 30. 1 tab dly in even.
    Hyperlipidem. in types 11a, 11b, III, IV, V
    where diet alone is insuffic.
    C/I: Hypersens., pregn., lact., liver/
    gallbladder dis., severe renal funct.

    full basket chart

    Bile Acid Sequestrant. Colestipol HCl 5 gr.
    PWDR: 50 packets x 5 g ea. 15-30 g dly.
    in div. doses in 3 or more ounces of
    liquid at least 1 hr. bef. or aft. taking
    any other drug.
    Adjunct ther. to diet in management
    elevated cholesterol levels, hypercholesterolemia,
    type II
    C/I: Hypersens., compl. obstruct. biliary

    Other therapeutic systems under Cardiovascular System